AVIENT CORPORATION (AVNT): what the price assumes

In the published model solve dated 2026-Q2, anchored at $43.40, AVIENT CORPORATION (AVNT) is priced for +14.5% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-09-07 · Exported: 2026-09-09 · Source: https://boothcheck.com/report/AVNT

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 9.6% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Relative, Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.5%); the inversion above states its own rate.

Per-Model Detail (n=15)

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

• Avient does not make plastic, it formulates it: colorants, additives and engineered compounds built to a customer's specification, including what the 10-K calls a full range of thermoset and thermoplastic composites, reinforced with glass, carbon, aramid, and ultrahigh molecular weight polyethylene fibers.
• The business is geographically spread rather than concentrated, with roughly 40% of sales in the United States and Canada, 36% in EMEA and 18% in Asia, which diversifies the demand cycle without escaping it.
• Gross debt of $1.92 billion is the constraint that decides how much time management has, sitting above seven times trailing operating profit, and the price on top of it needs about 16.9% annual operating-profit growth to work.

Bull Case

Read this as a mature business, because that is what it is, and mature businesses have to be judged on different evidence than growth ones. Nobody is underwriting a revenue line that compounds. The question is what a formulating company earns across a full cycle, how much of that reaches a shareholder, and whether the operator can hold position while the industry around it struggles. On the third question the current evidence is unusually clear.

The specialty chemicals cohort is in a bad stretch. Among the listed peers, CE reported a negative operating margin of 7.8%, HUN a negative 3.3%, OLN a negative 1.7% and ROG a negative 4.1%. Avient earned a positive 7.8% operating margin over the same trailing period. Being the profitable one in a cohort where several competitors are losing money at the operating line is not a small thing; it is what distinguishes a formulator that adds value from a producer that sells tonnage.

The revenue side tells the same story more quietly. Compared with the same peer group, CBT saw revenue fall 8.5%, EMN 7.7%, CE 5.5% and HUN 4.7% over the trailing year, while Avient's held roughly flat. A formulator is closer to the customer's specification and further from the commodity price, so its volumes move with what the customer designs rather than with the spot market. That is the whole reason the business exists in this form.

Management has been converting that resilience into structure rather than announcements. The filing attributes segment profit improvement to improved mix and cost savings from productivity and restructuring actions, and the company describes a portfolio it considers the broadest composite platform of solutions in its category. On the balance sheet it repaid $150.3 million of long-term borrowings during 2025 and net interest expense fell $7.0 million. Capital spending for the year was $106.6 million. The company's own read on liquidity is that cash flow from our current level of operations, available cash and available borrowings under our revolving credit facility provide adequate sources of liquidity.

The shareholder side is where a mature business proves itself, and here the record is consistent. The share count has actually shrunk slightly, moving about 0.1% a year over the last four years, so nothing has been financed by issuing stock. The quarterly dividend is 0.275 dollars a share and has now been raised in fifteen consecutive years. A company that keeps raising a dividend through a downcycle without diluting anyone is telling you something about how it expects the cycle to end.

Bear Case

The uncomfortable fact for a holder is that this is a stock priced for a recovery that has not started. Trailing operating income is $259.7 million, which is a 7.8% operating margin, and the market is paying about 20.2 times that figure. For those two numbers to sit together comfortably, operating profit has to grow roughly 16.9% a year over a five-year stretch. Nothing in the recent revenue trend produces that on its own. It has to come from margin repair, from volume returning, or from both, and none of it is visible in the trailing figures yet.

Look closely at the most recent print and the problem is sharper than the headline. First-quarter 2026 sales rose 3% to $847 million, but that included five points of favorable currency. Strip the currency and the underlying business went backwards. A recovery thesis whose most recent evidence is a weaker dollar is not yet a recovery thesis.

The competitive position is squeezed from two directions at once, and the filing describes both without softening either: Our competitors include commodity materials suppliers, which offer product substitutions based mostly on price, and suppliers of alternate solutions, which offer product substitutions or eliminations based mostly on disruptive technology. When customers are under cost pressure, the commodity substitute gets a hearing it would not otherwise get. That is precisely what happens in the part of the cycle the industry is currently in, and the peer numbers say the industry is in it: CBT revenue down 8.5%, EMN down 7.7%, CE down 5.5%.

Then there is the structure underneath. Gross debt of $1.92 billion sits above seven times trailing operating profit, and the borrowings come with strings. The credit agreements contain a number of customary financial and restrictive covenants that, among other things, limit our ability to: sell or otherwise transfer assets, including in a spin-off, incur additional debt or liens. A levered balance sheet in a downcycle does not usually break; it removes options. It makes the countercyclical acquisition harder, it makes the buyback smaller, and it makes each quarter of deferred recovery cost more than the last.

The company is also candid that its demand is not within its control, listing economic downturns, inflation or other uncertainty or volatility in the significant end markets that we serve among the factors that determine results. The bull answer, that Avient is the profitable operator in a cohort where several peers are not, is genuinely true and genuinely the reason to own it. It is also an argument about relative quality, and a price paying about 20.2 times a depressed operating profit is an argument about absolute recovery. Those are not the same claim.

Valuation

What the market is buying here is a recovery, and its size can be stated precisely. Today's quote values the enterprise at roughly 20.2 times trailing operating income, and that multiple implies operating profit compounding about 16.9% a year over a five-year stretch before settling into ordinary long-run growth. The arithmetic is unusually sensitive to the discount rate: each additional percentage point of cost of capital moves the implied growth requirement by about 7 points, which is a way of saying the answer is held together by assumptions about rates as much as by assumptions about polymers.

The methods split in a way that looks contradictory until you check what each one is comparing against. Peer multiple methods land above the price; on those the shares read as inexpensive, with the price at about 0.7 times where that family lands. The forward growth methods sit just below the quote, at about 1.15 times. The zero-growth earnings power methods are far below, with the price at roughly 4.24 times what those methods reach, and the book-value approaches also land under it. The apparent cheapness and the apparent expensiveness are measured against different things, and the peer comparison is the one to treat carefully: the sector reference multiple is being set by companies currently reporting operating losses, so looking cheap against that group is a weaker statement than it sounds.

The concrete requirement is a margin one. Avient earns about a 7.8% operating margin today, on trailing operating income of $259.7 million. What the quote needs is not a step change in the business model, but the operating line to widen and volumes to normalize at the same time, for several years running. Against the cohort the starting point is respectable: CE is at a negative 7.8% operating margin, HUN at a negative 3.3% and OLN at a negative 1.7%, while IOSP at 6.9% and NEU at 19.6% bracket where a healthy specialty formulator sits. Avient is in the healthy half. It is being priced as though it will move toward the top of it.

That is where the balance sheet becomes decisive rather than incidental. Gross debt of $1.92 billion sits above seven times trailing operating profit, which is a manageable position in a normal year and an uncomfortable one in a third consecutive soft year. The company has been shrinking it, repaying $150.3 million of long-term borrowings in 2025, and net interest expense fell $7.0 million as rates on its facilities came down. Capital spending of $106.6 million and a dividend of 1.10 dollars a share annually are both being funded without issuing stock; the share count has moved about 0.1% a year over the last four years. The whole position, then, rests on time. The structure can carry a slow recovery. The multiple is paying for a prompt one.

Catalysts

The most recent reported quarter set the terms of the debate. First-quarter 2026 sales grew 3% to $847 million, a figure that included roughly five points of favorable foreign exchange, and management held its full-year 2026 company-defined adjusted earnings guidance at a range of $2.93 to $3.17 per share. Holding guidance rather than raising it is the appropriate read on a quarter carried by currency.

Capital returns have continued on schedule through the soft patch. The board declared a quarterly dividend of $0.275 per share on July 16, 2026, payable on October 7, 2026 to holders of record on September 11, 2026, extending a streak of increases that now runs fifteen consecutive years. There has also been a change in the finance seat, with Giuseppe Di Salvo appointed Senior Vice President and Chief Financial Officer effective June 1, 2026. New chief financial officers frequently arrive with a fresh view of restructuring scope, which is worth watching in a company already running productivity programs.

The next scheduled information event is the second-quarter report on August 6, 2026. Two things in it matter more than the earnings line: whether volumes grow without help from currency, and whether the operating margin moves up rather than sideways. Those are the two variables that turn the recovery the price already assumes into something visible in the accounts.

Peer Cohorts (Per Segment, With Filing Citations)

Color, Additives and Inks (reported)

• CBT (Cabot Corporation)
• FY2025 10-K: …conductive additives and other materials for battery applications, and inkjet dispersions for high-speed industrial printing applications, including packaging and graphic arts. The recent investments we have made for growth in this segment, including with respect to these specific areas of focus, are described below…
• FY2025 10-K: …sale of specialty carbons and products for battery materials applications with a mix of global and regional companies. In recent years, a number of these companies that operate regionally have increased the export of products outside their region of manufacture. For fumed alumina, we compete primarily with one…
• EMN (EASTMAN CHEMICAL CO)
• FY2025 10-K: …gut health solutions preservation and hygiene Coatings Additives Polymers cellulosics polyesters polyolefins Additives and Solvents Texanol ™ Optifilm ™ ketones esters EastaPure ™ electronic chemicals specialty coalescents specialty solvents paint additives specialty polymers BASF SE Dow Inc. OXEA Celanese…
• FY2025 10-K: …us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueSegmentMember emn:AdditivesAndFunctionalProductsMember 2023-01-01 2023-12-31 0000915389 srt:NorthAmericaMember us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueSegmentMember emn:AdditivesAndFunctionalProductsMember 2025-01-01 2025-12-31…
• CE (CELANESE CORPORATION)
• FY2025 10-K: …value-in-use and is generally independent of changes in the cost of raw materials. Therefore, in general, margins may expand or contract in response to changes in raw material costs. See Note 22 - Revenue Recognition in the accompanying consolidated financial statements for further information. Acetyl Chain Products…
• FY2025 10-K: …customers under multi-year contracts and on the basis of long-standing relationships. Solvents and derivatives customers are primarily engaged in the production of paints, coatings and adhesives. We manufacture formaldehyde for our own use as well as for sale to a few regional customers. Emulsion, RDP and EVA…
• OLN (Olin Corporation)
• FY2025 10-K: …Foreign Jurisdictions that Prevent Inspections 99 Part III 100 Item 10. Directors, Executive Officers and Corporate Governance 100 Item 11. Executive Compensation 100 Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 100 Item 13. Certain Relationships and Related…
• FY2025 10-K: …of Contents 101.INS Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the XBRL document) 101.SCH XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL…
• HUN (Huntsman Corporation)
• FY2025 10-K: …economics. Jan Buberl , age 50, is Division President, Performance Products. Mr. Buberl was appointed to this position in August 2024. Prior to that time, Mr. Buberl served as Vice President-Americas for our Polyurethanes segment and as a director of our Chinese PO/MTBE joint venture with Sinopec since January 2019.…
• FY2025 10-K: …representative customers, raw materials and representative competitors of each of our business segments: Product lines End markets / applications Representative customers Raw materials Representative competitors Polyurethanes MDI Polyurethane chemicals are used to produce rigid and flexible foams, as well as…
• CC (Chemours Co)
• FY2025 10-K: …hemisphere for residential, commercial, and automotive air conditioning in the spring, which peaks in the summer months, and then declines in the fall and winter. Mobile air conditioning demand is slightly higher in the first half of the year due to the timing of automotive production shutdowns in the second half of…
• FY2025 10-K: …de-bottlenecking processes. If needed, unlocking additional capacity is in line with our stated intention to grow with our customers' needs over the long-term. Competition in the TiO 2 pigment market is based primarily on product performance (both product design and quality consistency), supply capability, technical…
• IOSP (INNOSPEC INC.)
• FY2025 10-K: …fuel efficiency, boost engine performance and reduce harmful emissions. Our Oilfield Services business supplies chemicals for drilling, completion, production and drag reducing agents ("DRA") which make oil and gas exploration and production more cost-efficient and environmentally friendly. Segment Information The…
• FY2025 10-K: …with developing customer needs. In addition, the business has developed further formulations in emollients, silicones and surfactants for the personal care, home care, agrochemical, construction, mining and other industrial markets. Fuel Specialties has continued to innovate, focused on bringing new technologies to…
• NEU (NEWMARKET CORPORATION)
• FY2025 10-K: …is characterized by the need to provide customers with cost-effective, technologically-capable products that meet or exceed industry specifications. The need to continually increase technology performance and lower cost through formulation technology and cost improvement programs is vital for success in this…
• FY2025 10-K: …Commonwealth of Virginia in 2004. Our principal executive offices are located at 330 South Fourth Street, Richmond, Virginia, and our telephone number is (804) 788-5000. 3 Table of Contents Business Segments For the periods presented in this Annual Report on Form 10-K, our business was composed of two segments,…

Specialty Engineered Materials (reported)

• CE (CELANESE CORPORATION)
• FY2025 10-K: Asia and consist of 51 global production facilities and an additional 20 strategic affiliate production facilities. As of December 31, 2025, we employed 11,434 people worldwide. Business Segment Overview We operate principally through two business segments: Engineered Materials and the Acetyl Chain. See Business…
• FY2025 10-K: …Engineered Materials business segment. The Company manages its Acetyl Chain business segment by leveraging its ability to sell chemicals externally to end-use markets or downstream to its acetate tow, intermediate chemistry, emulsion polymers, redispersible powders and ethylene vinyl acetate polymers businesses.…
• EMN (EASTMAN CHEMICAL CO)
• FY2025 10-K: Eastman's strategy is to target industries and markets where the Company can leverage its application development expertise to develop product offerings to provide differentiated value that addresses current and future customer and market needs. The Company's strategic marketing approach and capabilities leverage the…
• FY2025 10-K: …(Fo Gang) Specialty Resins Limited Chang Chun Petrochemical Co., Ltd. polyvinyl alcohol butyraldehyde 2-ethyl hexanol ethanol triethylene glycol vinyl acetate monomer transportation (automotive safety glass, automotive acoustic glass, and HUD) building and construction (PVB for architectural interlayers) Performance…
• HUN (Huntsman Corporation)
• FY2025 10-K: …of suppliers. We consume certain amines produced by our Performance Products segment and isocyanates produced by our Polyurethanes segment, which we use to formulate our Advanced Materials products. For additional information about our risks of raw material supply chain disruptions, see "Part I. Item 1A. Risk…
• FY2025 10-K: …aluminum panels and other steel materials to lighten structures in aerospace, automotive and other transportation. Our Advanced Materials segment is characterized by the breadth of our product offering, our expertise in complex chemistry, our long-standing relationships with our customers, our ability to develop and…
• CC (Chemours Co)
• FY2025 10-K: Specialized Solutions segment, we are a leading, global provider of refrigerants, thermal management solutions, propellants, foam blowing agents, and specialty solvents. Our Thermal & Specialized Solutions segment has held a leading position in the refrigerants market since the commercial introduction of Freon TM in…
• FY2025 10-K: …by product line and markets served. Our Advanced Performance Materials segment maintains a fleet of railcars, tank trucks, containers, and totes to deliver our products and support our supply chain needs. For the portion of the fleet that is leased, the related lease terms are usually staggered, which provides us…
• ROG (Rogers Corporation)
• FY2025 10-K: …the loss of any one of our larger customers would require a period of adjustment, during which the results of operations could be materially adversely impacted, we believe that such events could be successfully mitigated over a period of time due to the diversity of our customer base. We employ a technical sales and…
• FY2025 10-K: …Our competitors include commodity materials suppliers, which offer product substitutions based mostly on price, and suppliers of alternate solutions, which offer product substitutions or eliminations based mostly on disruptive technology. Certain of these competitors have greater financial and other resources than we…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.